Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X0002 Spray vs Celecoxib in Knee Osteoarthritis
NCT05324163Phase 3Completed
- Sponsor
- Techfields Pharma
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibuprofenamine hydrochloride in osteoarthritis (OA) (3 arms), sponsored by Techfields Pharma. Primary endpoint: Efficacy of ibuprofen hydrochloride spray compared with celecoxib capsules at 12 weeks. Started Sep 2021; status: completed.
02
Drugs
ibuprofenamine hydrochloride
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05324163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324163.